Informing Canada’s Cancer Drug Funding Decisions With Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

Current Oncology - Canada
doi 10.3747/co.20.1315
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

MultiMed Inc.

Related search

Clinician Participation in CADTH’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations

Current Oncology
Oncology
2017English

Pcn305 - Nice and the Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions in Oncology?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Drug Induced Steatohepatitis in Patient With Breast Cancer

Thai Journal of Hepatology
2018English

Impact of the Pan-Canadian Pricing Alliance (Pcpa) on Access to Drug Treatment Options for Canadian Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Recent Advances and Perspectives in Cancer Drug Design

Anais da Academia Brasileira de Ciencias
Multidisciplinary
2018English

Clinically Relevant Drug-Drug Interactions in Oncology

British Journal of Clinical Pharmacology
Pharmacology
1998English

Debating Drug Approval Decisions

Cancer Discovery
Oncology
2013English

Drug Pricing and Value in Oncology

Oncologist
Cancer ResearchMedicineOncology
2010English

A Review of Patient Perspectives on Generics Substitution: What Are the Challenges for Optimal Drug Use

GaBI Journal
Drug GuidesPharmacy
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy